Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: Results from the FREEDOM trial

Journal of Bone and Joint Surgery

Volumn 94, Issue 23, 2012, Pages 2113-2119

  Adami, Silvano ^a   Libanati, Cesar ^b   Boonen, Steven ^c   Cummings, Steven R ^d   Ho, Pei Ran ^b   Wang, Andrea ^b   Siris, Ethel ^e   Lane, Joseph ^f   Adachi, Jonathan D ^g   Bhandari, Mohit ^g   De Gregorio, Luiz ^h   Gilchrist, Nigel ⁱ   Lyritis, George ^j   Möller, Gerd ^b   Palacios, Santiago ^k   Pavelka, Karel ^l   Resch, Heinrich ^m   Roux, Christian ⁿ   Uebelhart, Daniel ^o  

^a UNIVERSITY OF VERONA   (Italy)

^b AMGEN INC   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Department of Medicine   (United States)

^f HOSPITAL FOR SPECIAL SURGERY   (United States)

^g MCMASTER UNIVERSITY   (Canada)

^h Center for Clinical and Basic Research   (Brazil)

ⁱ PRINCESS MARGARET HOSPITAL   (New Zealand)

^j Laboratory for the Study of Musculoskeletal System   (Greece)

^k Instituto Palacios de Salud Y Medicina de la Mujer   (Spain)

^l CHARLES UNIVERSITY   (Czech Republic)

^m MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁿ UNIVERSITÉ PARIS DESCARTES   (France)

^o Valmont   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; PLACEBO;

ADULT; AGED; ANEMIA; ANKLE FRACTURE; ARTHRITIS; ARTICLE; BLOOD VESSEL INJURY; BONE NECROSIS; CARPAL TUNNEL SYNDROME; CLAVICLE FRACTURE; CONTROLLED STUDY; DECUBITUS; DISEASE ASSOCIATION; DISLOCATION; DOUBLE BLIND PROCEDURE; FACE FRACTURE; FEMALE; FOOT FRACTURE; FOOT ULCER; FRACTURE HEALING; FRACTURE NONUNION; HAND FRACTURE; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; INFECTION; MAJOR CLINICAL STUDY; NEUROLOGIC DISEASE; OSTEOPOROSIS; PAIN; PATELLA FRACTURE; PELVIS FRACTURE; POSTMENOPAUSE; PRIORITY JOURNAL; PROSTHESIS FAILURE; RANDOMIZED CONTROLLED TRIAL; RIB FRACTURE; RISK FACTOR; SHOULDER FRACTURE; SKULL FRACTURE; TACHYCARDIA; THORAX PAIN; THROMBOEMBOLISM; WRIST DISEASE; WRIST FRACTURE;

EID: 84871503489     PISSN: 00219355     EISSN: 15351386     Source Type: Journal    
DOI: 10.2106/JBJS.K.00774     Document Type: Article

References (39)

1. Shi N, Foley K, Lenhart G, Badamgarav E. Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures. Bone. 2009 Dec;45(6):1084-90. Epub 2009 Aug 5.
2. Blume SW, Curtis JR. Medical costs of osteoporosis in the elderly Medicare population. Osteoporos Int. 2011 Jun;22(6):1835-44. Epub 2010 Dec 17.
3. Pike C, Birnbaum HG, Schiller M, Sharma H, Burge R, Edgell ET. Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US. Pharmacoeconomics. 2010;28(5):395-409. doi: 10.2165/11531040-000000000-00000.
4. Center JR, Bliuc D, Nguyen TV, Eisman JA. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA. 2007 Jan 24;297(4):387-94. (Pubitemid 46155800)
5. van Geel TA, van Helden S, Geusens PP, Winkens B, Dinant GJ. Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis. 2009 Jan;68(1):99-102. Epub 2008 Aug 3.
6. van Geel TA, Huntjens KM, van den Bergh JP, Dinant GJ, Geusens PP. Timing of subsequent fractures after an initial fracture. Curr Osteoporos Rep. 2010 Sep;8(3):118-22.
7. Andrade SE, Majumdar SR, Chan KA, Buist DS, Go AS, Goodman M, Smith DH, Platt R, Gurwitz JH. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med. 2003 Sep 22;163(17):2052-7. (Pubitemid 37151247)
8. Colón-Emeric C, Kuchibhatla M, Pieper C, Hawkes W, Fredman L, Magaziner J, Zimmerman S, Lyles KW. The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int. 2003 Nov;14(11):879-83. Epub 2003 Oct 3.
9. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000 Apr;15(4):721-39. (Pubitemid 30174026)
10. Boonen S, Autier P, Barette M, Vanderschueren D, Lips P, Haentjens P. Functional outcome and quality of life following hip fracture in elderly women: a prospective controlled study. Osteoporos Int. 2004 Feb;15(2):87-94. Epub 2003 Nov 7.
11. Brainsky A, Glick H, Lydick E, Epstein R, Fox KM, Hawkes W, Kashner TM, Zimmerman SI, Magaziner J. The economic cost of hip fractures in community-dwelling older adults: a prospective study. J Am Geriatr Soc. 1997 Mar;45(3):281-7. (Pubitemid 27114299)
12. Zimmerman S, Chandler JM, Hawkes W, Sloane PD, Hebel JR, Magaziner J, Martin AR, Girman CJ. Effect of fracture on the health care use of nursing home residents. Arch Intern Med. 2002 Jul 8;162(13):1502-8. (Pubitemid 34747484)
13. Ekman EF. The role of the orthopaedic surgeon in minimizing mortality and morbidity associated with fragility fractures. J Am Acad Orthop Surg. 2010 May;18(5):278-85.
14. Pountos I, Georgouli T, Blokhuis TJ, Pape HC, Giannoudis PV. Pharmacological agents and impairment of fracture healing: what is the evidence? Injury. 2008 Apr;39(4):384-94. Epub 2008 Mar 7.
15. Recker RR, Lewiecki EM, Miller PD, Reiffel J. Safety of bisphosphonates in the treatment of osteoporosis. Am J Med. 2009 Feb;122(2 Suppl):S22-32.
16. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005 Mar;90(3):1294-301. Epub 2004 Dec 14.
17. Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P, Peter R. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf. 2009;32(9):775-85. doi: 10.2165/00002018-200932090-00002.
18. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007 Nov 1;357(18):1799-809. Epub 2007 Sep 17.
19. Rozental TD, Vazquez MA, Chacko AT, Ayogu N, Bouxsein ML. Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. J Hand Surg Am. 2009 Apr;34(4):595-602.
20. Colón-Emeric C, Nordsletten L, Olson S, Major N, Boonen S, Haentjens P, Mesenbrink P, Magaziner J, Adachi J, Lyles KW, Hyldstrup L, Bucci-Rechtweg C, Recknor C; HORIZON Recurrent Fracture Trial. Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporos Int. 2011 Aug;22(8):2329-36. Epub 2010 Dec 9.
21. van der Poest Clement E, Patka P, Vandormael K, Haarman H, Lips P. The effect of alendronate on bone mass after distal forearm fracture. J Bone Miner Res. 2000 Mar;15(3):586-93. (Pubitemid 30134104)
22. Beaupre LA, Morrish DW, Hanley DA, Maksymowych WP, Bell NR, Juby AG, Majumdar SR. Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int. 2011 Mar;22(3):983-91. Epub 2010 Nov 4.
23. Adachi JD, Lyles KW, Colón-Emeric CS, Boonen S, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Bucci-Rechtweg C, Su G, Eriksen EF, Magaziner JS. Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial. Osteoporos Int. 2011 Sep;22(9):2539-49. Epub 2011 Jan 20.
24. Solomon DH, Hochberg MC, Mogun H, Schneeweiss S. The relation between bisphosphonate use and non-union of fractures of the humerus in older adults. Osteoporos Int. 2009 Jun;20(6):895-901. Epub 2008 Oct 9.
25. Weaver MJ, Miller MA, Vrahas MS. The orthopaedic implications of diphosphonate therapy. J Am Acad Orthop Surg. 2010 Jun;18(6):367-74.
26. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003 May 15;423(6937):337-42. (Pubitemid 40852708)
27. Delmas PD. Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. J Clin Densitom. 2008 Apr-Jun;11(2):325-38. Epub 2008 Apr 2.
28. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008 Jun;93(6):2149-57. Epub 2008 Apr 1.
29. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004 Jul;19(7):1059-66. Epub 2004 Mar 1.
30. Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J; Amg Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008 Aug;43(2):222-9. Epub 2008 Apr 26.
31. Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, Reid IR, Resch H, Siris E, Uebelhart D, Wang A, Weryha G, Cummings SR. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res. 2011 Mar;26(3):530-7. doi: 10.1002/jbmr.251.
32. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ; AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006 Feb 23;354(8):821-31. (Pubitemid 43290920)
33. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009 Aug 20;361(8):756-65. Epub 2009 Aug 11.
34. Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, Ebeling PR, Franek E, Yang YC, Egbuna OI, Boonen S, Miller PD. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011 Aug;26(8):1829-35. doi: 10.1002/jbmr.403.
35. Gehrig LM, Collinge C, Kaufman J, Lane JM, O'Connor MI, Tosi LL. Osteoporosis: management and densitometry for orthopaedic surgeons. Instr Course Lect. 2009;58:805-15.
36. Tosi LL, Gliklich R, Kannan K, Koval KJ. The American Orthopaedic Association's "own the bone" initiative to prevent secondary fractures. J Bone Joint Surg Am. 2008 Jan;90(1):163-73.
37. National Committee for Quality Assurance. The state of health care quality: value, variation and vulnerable populations. Washington, DC: National Committee for Quality Assurance; 2009. p 76-7.
38. Flick LM, Weaver JM, Ulrich-Vinther M, Abuzzahab F, Zhang X, Dougall WC, Anderson D, O'Keefe RJ, Schwarz EM. Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. J Orthop Res. 2003 Jul;21(4):676-84. (Pubitemid 36758211)
39. Ulrich-Vinther M, Andreassen TT. Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength. Calcif Tissue Int. 2005 Apr;76(4):280-6. Epub 2005 Apr 11.